Glaxosmithkline Plc Adr Stock Working Capital
| GSK Stock | USD 39.75 0.48 1.22% |
GlaxoSmithKline PLC ADR fundamentals help investors to digest information that contributes to GlaxoSmithKline PLC's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline PLC stock.
GlaxoSmithKline |
GlaxoSmithKline PLC ADR Company Working Capital Analysis
GlaxoSmithKline PLC's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current GlaxoSmithKline PLC Working Capital | (2.42 B) |
Most of GlaxoSmithKline PLC's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline PLC ADR is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
According to the company's disclosures, GlaxoSmithKline PLC ADR has a Working Capital of (2.42 Billion). This is 669.48% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The working capital for all United States stocks is significantly higher than that of the company.
GlaxoSmithKline Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline PLC's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline PLC could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline PLC by comparing valuation metrics of similar companies.GlaxoSmithKline PLC is currently under evaluation in working capital category among related companies.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.46 | ||||
| Return On Asset | 0.0881 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.20 % | ||||
| Current Valuation | 172.41 B | ||||
| Shares Outstanding | 2.04 B | ||||
| Shares Owned By Institutions | 14.42 % | ||||
| Number Of Shares Shorted | 4.83 M | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 4.96 X | ||||
| Price To Sales | 2.75 X | ||||
| Revenue | 30.33 B | ||||
| Gross Profit | 19.92 B | ||||
| EBITDA | 9.29 B | ||||
| Net Income | 4.93 B | ||||
| Cash And Equivalents | 3.72 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 18.02 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 3.29 X | ||||
| Cash Flow From Operations | 6.35 B | ||||
| Short Ratio | 1.83 X | ||||
| Earnings Per Share | 2.99 X | ||||
| Price To Earnings To Growth | 1.09 X | ||||
| Target Price | 45.32 | ||||
| Number Of Employees | 70.21 K | ||||
| Beta | 0.27 | ||||
| Market Capitalization | 81.18 B | ||||
| Total Asset | 59.01 B | ||||
| Retained Earnings | 7.24 B | ||||
| Working Capital | (2.42 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 5.32 % | ||||
| Net Asset | 59.01 B | ||||
| Last Dividend Paid | 0.58 |
About GlaxoSmithKline PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline PLC ADR's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline PLC ADR based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GlaxoSmithKline PLC in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GlaxoSmithKline PLC's short interest history, or implied volatility extrapolated from GlaxoSmithKline PLC options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out GlaxoSmithKline PLC Piotroski F Score and GlaxoSmithKline PLC Altman Z Score analysis. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for GlaxoSmithKline Stock analysis
When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.